Summary:
- The U.S. FDA has granted accelerated approval to Bristol Myers Squibb’s ZENBEXUS (iberdomide), a novel CELMoD agent, for the treatment of adult patients with relapsed or refractory multiple myeloma.
- This therapy is indicated for use in combination with daratumumab and hyaluronidase-fihj and dexamethasone, specifically for patients who have received at least one prior line of therapy, including an immunomodulatory agent and a proteasome inhibitor.
- The approval is supported by clinical data demonstrating the efficacy of this targeted protein degradation approach in addressing treatment-resistant plasma cell malignancies.